# The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients

> **NCT01493960** · PHASE3 · COMPLETED · sponsor: **InDex Pharmaceuticals** · enrollment: 131 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Cobitolimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01493960
- **Lead sponsor:** InDex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-06
- **Final completion:** 2014-03
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01493960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01493960, "The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01493960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*